trending Market Intelligence /marketintelligence/en/news-insights/trending/JaQbP_8UP8wH9MBs3_-53g2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Japan IP court rules in Lilly's favor on Alimta patents

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Japan IP court rules in Lilly's favor on Alimta patents

The Japan IP High Court ruled in favor of Eli Lilly & Co. in the invalidation trials initiated by Sawai Pharmaceutical Co. Ltd. regarding Lilly's vitamin regimen patents for Alimta.

The ruling has confirmed the decision of the Japanese Patent Office made in 2015, which upheld the validity of the Alimta vitamin regimen patents.

If the patents are upheld through all challenges, they could provide intellectual property protection for Alimta in Japan until June 2021. Lilly will take necessary actions to defend and enforce the patents.